Swedish private equity firm EQT wants to acquire diagnostics specialist Qiagen for €10.8 billion, or €46.50 per share. The ...

Icelandic biotech Arctic Therapeutics has raised $21.5 million (€19.1 million) in an oversubscribed round to take two drug ...

At the IZB in Martinsried, Invitris is developing a cell-free platform to turn ­digital sequences into proteins, antibodies ...

Sanofi’s Cenrifki (tolebrutinib) has been approved in the EU as the first disability-targeting medicine for adults with secondary progressive multiple sclerosis (SPMS) without relapses in the previous ...

British rare disease specialist Ambrose Healthcare has acquired Dutch biotech AM-Pharma for up to €161 million, adding an enzyme replacement therapy to its pipeline and a development base in Utrecht.

The Swiss pharmaceutical group has agreed to another, deeper ADC partnership with China’s Hansoh Pharma, with potential ...

Oxford-based OMass Therapeutics has raised $310 million (€276 million) in a Series C financing to advance its small-molecule ...

Following Fresenius’ launch of a €200 million healthcare venture fund in July, we invited Thomas Thestrup, managing director ...

French biotech OSE Immunotherapeutics has reported higher one-year survival rates with two combinations of its cancer vaccine Tedopi compared with chemotherapy alone in a Phase 2 lung cancer trial.

Italy's Newron Pharmaceuticals has disclosed that the FDA kept U.S. enrollment in a Phase 3 trial of its schizophrenia drug evenamide on hold, citing five deaths across all the drug's clinical studies ...

Each month, the European Medicines Agency’s human medicines committee (CHMP) weighs in on which drugs should reach European ...

Zealand Pharma shares fell about 4% in Thursday trading after new Phase 2 results for its Roche-partnered obesity drug petrelintide showed encouraging weight loss but a modest improvement in blood ...